Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
NCT00500617 · View on ClinicalTrials.gov ↗
Study Summary
The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD). The Corus CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR (RT-PCR) to quantify the expression of multiple genes from circulating peripheral blood cells to assess the presence of clinically significant CAD in a patient.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Corus CAD (ASGES)
Study Locations (10)
California
- CV Medical Group Southern California — Beverly Hills
- Scripps HealthCare — La Jolla
Alaska
- Alaska Heart Institute — Anchorage
District of Columbia
- Washington Hospital Medical Center — Washington D.C.
Georgia
- Fuqua Heart Center of Atlanta — Atlanta
Minnesota
- Minneapolis Heart Institute — Minneapolis
North Carolina
- Duke University Medical Center — Durham
Pennsylvania
- Allegheny Hospital — Pittsburgh
Tennessee
- Vanderbilt University Medical Center — Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,350 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-09 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500617
The ClinicalTrials.gov registry entry for NCT00500617 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4,350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CardioDx, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 8 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention — of which Corus CAD (ASGES) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00500617 reports 10 study locations spanning 9 distinct geographic areas — top geographies include California, Alaska, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00500617 about?
NCT00500617 is a clinical study titled "Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree". The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD). The Corus CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR (RT-PCR) to quantify the expression of mul...
What is the current status of trial NCT00500617?
This trial is currently completed. The enrollment target is 4,350 participants. The study started on 2007-07. Estimated completion is 2011-09.
What conditions does trial NCT00500617 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Coronary Artery Disease, Chest Pain, Coronary Heart Disease, Angina Pectoris. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00500617?
The interventions under investigation include: Corus CAD (ASGES) (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00500617?
This trial is sponsored by CardioDx, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00500617 being conducted?
This trial has 10 study locations across Alaska, California, District of Columbia, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.